Glucocorticoids and gut bacteria: "The GALF Hypothesis" in the metagenomic era.
Level 5 - mechanism / opinion, no new human data
Narrative review presenting a mechanistic hypothesis without systematic review methods or original clinical data
PubMed 28624548 · doi:10.1016/j.steroids.2017.06.002
What was done
This narrative review synthesizes literature evaluating the endocrine function of the gut microbiota, specifically exploring how bacterial metabolism of endogenous adrenocorticosteroids may contribute to essential hypertension and colorectal cancer. It outlines the GALF hypothesis, comparing putative bacterially derived glycerrhetinic acid-like factors to known mechanisms of 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2) inhibition seen in licorice ingestion and genetic apparent mineralocorticoid excess syndrome.
What was found
The abstract reports no numerical findings or quantitative effect sizes. It describes a proposed pathway wherein gut bacterial metabolites of glucocorticoids enter the portal circulation, reach the kidney, and inhibit 11β-HSD2, preventing normal inactivation of cortisol and allowing excess mineralocorticoid receptor activation with resulting sodium and water retention. The authors also note a hypothesized protective role for these bacterial metabolites in colorectal cancer.
Why it matters
The paper outlines a conceptual framework connecting microbial steroid metabolism to host blood pressure regulation, proposing a potential gut-mediated mechanism underlying cases of essential hypertension.
Limits
As a narrative review, the paper provides no original experimental or clinical data, and the abstract includes no quantitative measurements or sample sizes. The causal link between specific bacterial strains, metabolite production, and human hypertension remains theoretical and unproven based on this abstract.
Cited by
- supports Gut microbes metabolize cortisol into byproducts that alter renal potassium-sodium ratios, increasing fluid retention and raising blood pressure.